PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 15 | 4 | 231–238
Article title

The impact of treatment exposure on diabetes biomarkers among Jordanian breast cancer women: a connection through FBG, C-peptide and HOMA-IR

Content
Title variants
PL
Wpływ leczenia na biomarkery cukrzycy u kobiet z rakiem piersi w Jordanii: związek z glikemią na czczo, peptydem C i wskaźnikiem HOMA-IR
Languages of publication
EN
Abstracts
EN
Background: Breast cancer is the most frequently occurring and life-threatening malignant tumor in women. The evidence that associates diabetes’ biomarkers with breast cancer is highly controversial. Aims: To evaluate diabetes’ biomarkers in breast cancer patients according to type of treatment exposure, breast cancer severity and menopausal status. Material and methods: A total of 396 breast cancer patients aged between 25 and 65 years attending breast cancer clinics were evaluated. The experimental design permitted to include 134 newly-diagnosed breast cancer patients who were not exposed to any type of interventions and 262 recently diagnosed breast cancer patients (up to three months). Recently, group members were subdivided in two subgroups to control exposure to therapy specially chemotherapy. The patients were further divided according to breast cancer stages and postmenopausal status. Diabetes biomarkers consisted of fasting blood glucose (FBG), C-peptide and HOMA-IR. Results: The high FBG was more prevalent in advance (24.1%) than early (10.6%) stage breast cancer. Compared with premenopausal breast cancer patients, postmenopausal breast cancer patients had higher prevalence of abnormal FBG (21.0% vs. 11.1%). The differences were also significant in the mean of FBG (103.0 ± 1.5 vs. 89.0 ± 0.0 mg/dL). In postmenopausal breast cancer patients, FBG was higher in the recently diagnosed whom expose to treatments including chemotherapy (106.5 ± 1.7 mg/dL vs. 126.2 ± 1.2 mm Hg) compared to the newly-diagnosed group whom not yet expose to any kind of treatment interventions. Conclusion: Diabetes was prevalent among breast cancer patients and it was higher in postmenopausal and advanced stage breast cancer women. The burden of diabetes on treatment expose breast cancer women tend to be high and warrants closer attention by health care provider to improved outcomes after diagnosis and treatment exposure.
PL
Wstęp: Rak piersi to najczęstszy zagrażający życiu nowotwór złośliwy u kobiet. Doniesienia dotyczące związku cukrzycy z rakiem piersi są wysoce kontrowersyjne. Cele: Analiza biomarkerów cukrzycy u pacjentek z rakiem piersi w zależności od ekspozycji na leczenie, stopnia zaawansowania nowotworu i statusu menopauzalnego. Materiał i metody: Do badania włączono 396 pacjentek z rakiem piersi w wieku od 25 do 65 lat, które zgłosiły się do klinik specjalizujących się w leczeniu tej choroby. Plan badania dopuszczał włączenie 134 pacjentek z nowo rozpoznanym nowotworem, które nie otrzymały jeszcze leczenia w żadnej postaci, oraz 262 pacjentek z nowotworem rozpoznanym w ciągu ostatnich trzech miesięcy. Następnie uczestniczki podzielono na dwie podgrupy w celu kontroli ekspozycji na leczenie, szczególnie chemioterapię. Pacjentki podzielono także na podstawie stopnia zaawansowania nowotworu i statusu menopauzalnego. Oceniono następujące biomarkery cukrzycy: glikemię na czczo, peptyd C oraz wskaźnik HOMA-IR. Wyniki: Wysoki poziom glukozy na czczo obserwowano częściej u chorych z zaawansowanym rakiem piersi (24,1%) niż u kobiet z nowotworem we wczesnym stadium zaawansowania (10,6%). W porównaniu z pacjentkami przed menopauzą chore po menopauzie charakteryzowało częstsze występowanie nieprawidłowej glikemii na czczo (21,0% vs 11,1%). Różnice były także istotne dla średniej wartości glukozy na czczo (103,0 ± 1,5 vs 89,0 ± 0,0 mg/dl). W przypadku kobiet po menopauzie wartości te były wyższe u chorych z rakiem piersi, które otrzymały leczenie, w tym chemioterapię (106,5 ± 1,7 mg/dl vs 126,2 ± 1,2 mm Hg), w porównaniu z nowo zdiagnozowanymi pacjentkami, u których nie rozpoczęto jeszcze leczenia w jakiejkolwiek postaci. Wnioski: W grupie badanych chorych cukrzyca była częstym problemem. Chorobę tą częściej obserwowano u kobiet po menopauzie i z zaawansowanym nowotworem. Odnotowano też istotną zależność między cukrzycą a ekspozycją na leczenie raka piersi. Na korelację tę należy zwrócić szczególną uwagę po rozpoznaniu choroby i wdrożeniu leczenia.
Discipline
Publisher

Year
Volume
15
Issue
4
Pages
231–238
Physical description
Contributors
  • Department of Allied Medical Sciences, Al-Zarqa University College, Al-Balqa’ Applied University, Al-Salt, Jordan, safaa84@bau.edu.jo
  • Department of Nutrition and Food Technology, Faculty of Agriculture, University of Jordan, Amman, Jordan
  • Breast Cancer Unit, Department of General Surgery, King Hussein Medical Center, Amman, Jordan
References
  • 1. American Diabetes Association (ADA): Standards of medical care in diabetes – 2016. Introduction. Diabetes Care 2016; 39 Suppl 1: S1–S2. Available from: http://care.diabetesjournals.org/ content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf.
  • 2. Intentional Diabetes Federation (IDF): What is diabetes? In: IDS Diabetes Atlas. 7th ed., 2015: 22–32. Available from: http://www. diabetesatlas.org [cited: April 2016].
  • 3. Unwin N, Gan D, Whiting D: The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract 2010; 87: 2–3.
  • 4. Ajlouni K, Khader YS, Batieha A et al.: An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complications 2008; 22: 317–324.
  • 5. Khader Y, Bateiha A, El-Khateeb M et al.: High prevalence of the metabolic syndrome among Northern Jordanians. J Diabetes Complications 2007; 21: 214–219.
  • 6. Al-Odat AZ, Ahmad MN, Haddad FH: References of anthropometric indices of central obesity and metabolic syndrome in Jordanian men and women. Diabetes Metab Syndr 2012; 6: 15–21.
  • 7. Gouveri E, Papanas N, Maltezos E: The female breast and diabetes. Breast 2011; 20: 205–211.
  • 8. Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007; 86: s823–s835.
  • 9. Healy LA, Ryan AM, Rowley S et al.: Obesity increases the risk of postmenopausal breast cancer and is associated with more advanced stage at presentation but no impact on survival. Breast J 2010; 16: 95–97.
  • 10. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.
  • 11. Gaudet MM, Patel AV, Teras LR et al.: Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet 2013; 4: 156–166.
  • 12. Eliassen AH, Tworoger SS, Mantzoros CS et al.: Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 2007; 16: 161–164.
  • 13. Jordan Breast Cancer Program. 2009, Breast Cancer in Jordan. JBCP, The King Hussein Cancer Foundation and Center. Amman, Jordan. Available from: http://www.khcc.jo/section/jordan-breast-cancer-program.
  • 14. Agnoli C, Berrino F, Abagnato CA et al.: Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010; 20: 41–48.
  • 15. Hardefeldt PJ, Edirimanne S, Eslick GD: Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer 2012; 19: 793–803.
  • 16. Lipscombe LL, Fischer HD, Yun L et al.: Association between tamoxifen treatment and diabetes: a population-based study. Cancer 2012; 118: 2615–2622.
  • 17. Carstensen B, Witte DR, Friis S: Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012; 55: 948–958.
  • 18. Goodwin PJ, Thompson AM, Stambolic V: Diabetes, metformin, and breast cancer: lilac time? J Clin Oncol 2012; 30: 2812–2814.
  • 19. Kaaks R, Lundin E, Rinaldi S et al.: Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002; 13: 307–316.
  • 20. Muti P, Quattrin T, Grant BJ et al.: Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1361–1368.
  • 21. Verheus M, Peeters PH, Rinaldi S et al.: Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006; 119: 659–667.
  • 22. Ligibel JA, Campbell N, Partridge A et al.: Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 2008; 26: 907–912.
  • 23. Duggan C, Irwin ML, Xiao L et al.: Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011; 29: 32–39.
  • 24. Bjørge T, Lukanova A, Jonsson H et al.: Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010; 19: 1737–1745.
  • 25. Hu FB, Manson JE, Stampfer MJ et al.: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790–797.
  • 26. Sobin LH, Wittekind C (eds.): TNM Classification of Malignant Tumours. 6th ed., International Union against Cancer (UICC), Wiley-Liss, New York 2002.
  • 27. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359–377.
  • 28. Arkoob K, Al-Nsour M, Al-Nemry O et al.: Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J 2010; 16: 1032–1038.
  • 29. Lee RD, Nieman DC: Nutritional Assessment. 5th ed., McGrawHill, New York 2010.
  • 30. Obesity: Preventing and Managing the Global Epidemic. World Health Organization, Report of a WHO Consultation (WHO Technical Report Series 894), 2000. Available from: http://www. who.int/nutrition/publications/obesity/WHO_TRS_894/en/.
  • 31. Matthews DR, Hosker JP, Rudenski AS et al.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
  • 32. Obeidat AA, Ahmad MN, Haddad FH et al.: Leptin and uric acid as predictors of metabolic syndrome in Jordanian adults. Nutr Res Pract 2016; 10: 411–417.
  • 33. Autier P, Koechlin A, Boniol M et al.: Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. Cancer Causes Control 2013; 24: 873–883.
  • 34. Holmes MD, Liu S, Hankinson SE et al.: Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol 2004; 159: 732–759.
  • 35. Bowker SL, Richardson K, Marra CA et al.: Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 2011; 34: 2542–2544.
  • 36. Johansson H, Gandini S, Guerrieri-Gonzaga A et al.: Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008; 68: 9512–9518.
  • 37. Kabat GC, Kim M, Chlebowski RT et al.: A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2046–2053.
  • 38. Goodwin PJ, Ennis M, Pritchard KI et al.: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42–51.
  • 39. Bonser AM, Garcia-Webb P: C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 1984; 19: 297–352.
  • 40. Chen CH, Tsai ST, Chou P: Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. Int J Cardiol 1999; 68: 179–186.
  • 41. Irwin ML, Duggan C, Wang CY et al.: Fasting C-peptide levels and death resulting from all causes and breast cancer: the Health, Eating, Activity, and Lifestyle Study. J Clin Oncol 2011; 29: 47–53.
  • 42. Al-Zeidaneen S, Ahmad M, Al-Ebuose A et al.: Interactive role of obesity indices on breast cancer severity in Jordanian women. EJBPS 2017; 4: 637–644.
  • 43. Rosato V, Bosetti C, Talamini R et al.: Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22: 2687–2692.
  • 44. Hvidtfeldt UA, Gunter MJ, Lange T et al.: Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1203–1212.
  • 45. Maskarinec G, Jacobs S, Park SY et al.: Type II diabetes, obesity, and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2017; 26: 854–861.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-aba99cc5-17ba-41cd-99c9-ce42a1648f46
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.